Dapoxetine
drugOn this page
Also known as DapoxetinaKutubLY-210448SID170466555SID174006832Dapoxetine hydrochloride (Priligy)
Summary
Dapoxetine (CHEMBL2110900) is a phase-3 clinical-stage small molecule (ATC G04BX14) targeting SLC6A4; indicated across 3 conditions including erectile dysfunction and physiological sexual disorder.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- ATC class: G04BX14
- Targets: 1 (SLC6A4)
- Indications: 3 conditions
- Clinical trials: 18
- Chemistry: 305.4 Da · C21H23NO
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2110900 |
| Name | Dapoxetine |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 71353 |
| ATC | G04BX14 |
| Molecular formula | C21H23NO |
| Molecular weight | 305.4 |
| InChIKey | USRHYDPUVLEVMC-FQEVSTJZSA-N |
SMILES: CN(C)[C@@H](CCOC1=CC=CC2=CC=CC=C21)C3=CC=CC=C3
IUPAC name: (1S)-N,N-dimethyl-3-naphthalen-1-yloxy-1-phenylpropan-1-amine
Also known as: Dapoxetina, Dapoxetine, Kutub, LY-210448, SID170466555, SID174006832, DAPOXETINE, dapoxetine, Dapoxetine hydrochloride (Priligy)
Parent form; salt/anhydrous children: CHEMBL2106574
Patent coverage: 1,727 distinct patent families (5,235 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 5,206 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| SLC6A4 | SERT | Inhibition | 8.95 | 0.7% | P31645 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): SLC6A4.
Top Reactome pathways
5 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Neurotransmitter clearance | 1 | SLC6A4 |
| Transmission across Chemical Synapses | 1 | SLC6A4 |
| Neuronal System | 1 | SLC6A4 |
| Serotonin clearance from the synaptic cleft | 1 | SLC6A4 |
| SLC-mediated transport of neurotransmitters | 1 | SLC6A4 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| response to hypoxia | 1 |
| neurotransmitter transport | 1 |
| amino acid transport | 1 |
| response to nutrient | 1 |
| memory | 1 |
| circadian rhythm | 1 |
| response to xenobiotic stimulus | 1 |
| response to toxic substance | 1 |
| positive regulation of gene expression | 1 |
| positive regulation of serotonin secretion | 1 |
| obsolete monoamine transport | 1 |
| negative regulation of cerebellar granule cell precursor proliferation | 1 |
| negative regulation of synaptic transmission, dopaminergic | 1 |
| response to estradiol | 1 |
| sodium ion transmembrane transport | 1 |
Indications & clinical
Indications
3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| erectile dysfunction | 3 | MONDO:0005362 | EFO:0004234 |
| physiological sexual disorder | 3 | MONDO:0002134 | EFO:0004714 |
| premature ejaculation | 3 | MONDO:0001780 | EFO:0803321 |
Clinical trials
Total trials: 18.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 11 |
| PHASE1/PHASE2 | 2 |
| PHASE1 | 2 |
| Not specified | 2 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06425224 | PHASE3 | RECRUITING | Effectiveness and Safety of TENS Therapy for Premature Ejaculation |
| NCT00210613 | PHASE3 | COMPLETED | A Study of Withdrawal Effects With Dapoxetine in the Treatment of Premature Ejaculation |
| NCT00210704 | PHASE3 | COMPLETED | A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation |
| NCT00211094 | PHASE3 | COMPLETED | A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation |
| NCT00211107 | PHASE3 | COMPLETED | A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation. |
| NCT00229073 | PHASE3 | COMPLETED | A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation |
| NCT01063855 | PHASE3 | COMPLETED | Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction |
| NCT01063881 | PHASE3 | COMPLETED | The Asia-Pacific Flexible Dose Study of Dapoxetine and Patient Satisfaction in Premature Ejaculation Therapy |
| NCT01230762 | PHASE3 | COMPLETED | An Open-Label Study of the Long-Term Safety of Dapoxetine HCl in the Treatment of Rapid Ejaculation |
| NCT04085354 | PHASE3 | COMPLETED | Evaluation of the Clinical Efficacy and Safety of Dapoxetine, Combined Dapoxetine With Folic Acid and Combined Dapoxetine With Vitamin B12 in Treatment of Patients With Premature Ejaculation |
| NCT04361305 | PHASE3 | UNKNOWN | Observational Study of Pharmacological Treatment for Premature Ejaculation Concurrent With Erectile Dysfunction |
| NCT07081659 | PHASE2/PHASE3 | COMPLETED | On-demand Silodosin 4mg vs Dapoxetine 60mg in Treatment of Primary Premature Ejaculation |
| NCT01419470 | PHASE1/PHASE2 | COMPLETED | Safety, Tolerability, Pharmacokinetics and Efficacy of YHD1044 |
| NCT04850703 | PHASE1/PHASE2 | COMPLETED | Brain Networks Implicated in Lifelong Premature Ejaculation Patients |
| NCT01928563 | PHASE1 | UNKNOWN | Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Dapoxetine |
| NCT02485041 | PHASE1 | COMPLETED | Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 100mg |
| NCT03018743 | Not specified | UNKNOWN | Discontinuation of Dapoxetine Treatment in Patients With Premature Ejaculation |
| NCT03583112 | Not specified | UNKNOWN | Investigation of the Changes of Brain Structure and Function in Premature Ejaculation Patients and the Effects of Dapoxetine on Central Neural Activity in Premature Ejaculation Patients |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline, but PharmGKB curates 1 clinical and 5 variant annotation(s) for this drug (gene-keyed; see PharmGKB).
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
442 molecules share ≥1 primary target. Top 60 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| CRIZOTINIB | ChEMBL + PubChem | Phase 4 (approved) | SLC6A4 |
| GENTIAN VIOLET | ChEMBL + PubChem | Phase 4 (approved) | SLC6A4 |
| OLODATEROL | ChEMBL + PubChem | Phase 4 (approved) | SLC6A4 |
| TADALAFIL | ChEMBL + PubChem | Phase 4 (approved) | SLC6A4 |
| TAFENOQUINE | ChEMBL + PubChem | Phase 4 (approved) | SLC6A4 |
| UMECLIDINIUM | ChEMBL + PubChem | Phase 4 (approved) | SLC6A4 |
| ACETOPHENAZINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| ACRIVASTINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| ALECTINIB | ChEMBL | Phase 4 (approved) | SLC6A4 |
| ALLOPURINOL | ChEMBL | Phase 4 (approved) | SLC6A4 |
| AMBENONIUM | ChEMBL | Phase 4 (approved) | SLC6A4 |
| AMIODARONE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| AMITRIPTYLINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| AMOXAPINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| AMPHOTERICIN B | ChEMBL | Phase 4 (approved) | SLC6A4 |
| APOMORPHINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| ARFORMOTEROL | ChEMBL | Phase 4 (approved) | SLC6A4 |
| ARIPIPRAZOLE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| ASENAPINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| ASTEMIZOLE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| ATOMOXETINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| ATRACURIUM | ChEMBL | Phase 4 (approved) | SLC6A4 |
| AZATHIOPRINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| AZELASTINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| BALSALAZIDE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| BAZEDOXIFENE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| BENFLUOREX | ChEMBL | Phase 4 (approved) | SLC6A4 |
| BENZPHETAMINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| BENZTROPINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| BENZYDAMINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| BEPRIDIL | ChEMBL | Phase 4 (approved) | SLC6A4 |
| BOSUTINIB | ChEMBL | Phase 4 (approved) | SLC6A4 |
| BREXPIPRAZOLE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| BROMHEXINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| BROMODIPHENHYDRAMINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| BROMPERIDOL | ChEMBL | Phase 4 (approved) | SLC6A4 |
| BROMPHENIRAMINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| BUPROPION | ChEMBL | Phase 4 (approved) | SLC6A4 |
| BUTENAFINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CABERGOLINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CALCIPOTRIENE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CALCITRIOL | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CANAGLIFLOZIN | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CARBINOXAMINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CARIPRAZINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CARVEDILOL | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CEFONICID | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CELECOXIB | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CETIRIZINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CHLORHEXIDINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CHLORPHENIRAMINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CHLORPHENTERMINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CHLORPROMAZINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CHLORPROTHIXENE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CINACALCET | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CINNARIZINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CISAPRIDE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CITALOPRAM | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CLEMASTINE | ChEMBL | Phase 4 (approved) | SLC6A4 |
| CLIDINIUM | ChEMBL | Phase 4 (approved) | SLC6A4 |
Related Atlas pages
- Genes: SLC6A4
- Diseases: erectile dysfunction, physiological sexual disorder, premature ejaculation
- Drugs: Crizotinib, Olodaterol, Tadalafil, Tafenoquine, Umeclidinium, Acetophenazine, Acrivastine, Alectinib, Allopurinol, Ambenonium, Amiodarone, Amitriptyline, Amoxapine, Amphotericin B, Apomorphine, Arformoterol, Aripiprazole, Asenapine, Astemizole, Atomoxetine, Atracurium, Azathioprine, Azelastine, Balsalazide, Bazedoxifene, Benfluorex, Benzphetamine, Benztropine, Benzydamine, Bepridil, Bosutinib, Brexpiprazole, Bromhexine, Bromodiphenhydramine, Bromperidol, Brompheniramine, Bupropion, Butenafine, Cabergoline, Calcipotriene, Calcitriol, Canagliflozin, Carbinoxamine, Cariprazine, Carvedilol, Cefonicid, Celecoxib, Cetirizine, Chlorhexidine, Chlorpheniramine, Chlorphentermine, Chlorpromazine, Chlorprothixene, Cinacalcet, Cinnarizine, Cisapride, Citalopram, Clemastine, Clidinium